Mach7 Technologies Limited (M7T) Fair Value & Analysis
Healthcare · AU · Market cap A$75.2M
Fair value as of: Jun 24, 2026
Analysis
Mach7 Technologies Limited (M7T) currently trades at A$0.2950, while our model-based Fair Value estimate is A$0.1100 — implying the stock looks roughly 62.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients' medical images; vendor-neutral archive (VNA), a vendor-agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. The company also provides workflow applications, such as a universal worklist, quality control (QC) tools designed for technologists' workflows; image sharing and exchange capabilities; teleradiology services; and additional specialized tools to serve departmental patient care needs. Mach7 Technologies Limited was founded in 2007 and is headquartered in South Burlington, Vermont.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Mach7 Technologies Limited (M7T) undervalued?
What is the fair value of M7T?
What is the quality score of M7T?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.